Business Context and Reporting Period
This Form 6-K filing by Nano-X Imaging Ltd. (Nanox) covers the month of August 2026. The report details the completion of a registered direct offering on August 7, 2026, executed pursuant to a shelf registration statement on Form F-3.
Key Financial Metrics
- Gross Proceeds: Approximately $8.0 million.
- Offering Structure: Sale of 8,000,000 ordinary shares (or pre-funded warrants) and 8,000,000 ordinary warrants to a single institutional investor.
- Purchase Price: $1.00 per ordinary share and accompanying ordinary warrant (or $0.9999 per pre-funded warrant and accompanying ordinary warrant).
- Placement Agent Fees: 5.0% of gross proceeds (cash fee) plus reimbursement of up to $50,000 in legal fees.
- Use of Proceeds: Working capital and general corporate purposes.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics; it focuses solely on the capital raise transaction.
Material Changes and Transaction Details
The primary material change is the dilution of existing shareholders due to the issuance of 8,000,000 new shares (or pre-funded warrants) and 8,000,000 warrants. Key terms include:
- Pre-Funded Warrants: Exercise price of $0.0001, immediately exercisable, no expiration until fully exercised.
- Ordinary Warrants: Exercise price of $1.15, exercisable beginning six months after issuance, expiring five years from the closing date.
- Ownership Cap: Exercise is limited to prevent the Purchaser's beneficial ownership from exceeding 4.99% of ordinary shares.
Guidance, Outlook, and Restrictions
Management intends to utilize net proceeds for working capital and general corporate purposes. The filing outlines specific restrictions imposed by the transaction:
- Lock-Up Period: Officers and directors are restricted from selling shares or share equivalents for 30 days following the closing, subject to Placement Agent consent.
- Issuance Restriction: The Company is restricted from issuing or announcing the issuance of ordinary shares or equivalents for 30 days following the agreement date, with limited exceptions (e.g., employee benefit plans).
- Risks and Contingencies: The filing notes that representations and warranties are subject to limitations agreed upon by the contracting parties and are not complete without reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 5.0% placement fee and legal expense reimbursements.
- Confirm the current cash balance and runway extension provided by the $8.0 million gross raise.
- Review the full text of the Securities Purchase Agreement (Exhibit 4.1) for specific covenants and representations.
- Assess the impact of the 4.99% beneficial ownership cap on the Purchaser's ability to exercise warrants.
- Monitor the 30-day lock-up expiration for potential selling pressure from officers and directors.